

Please sign (+) inside this box → ☐

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	09/656,084	
	Filing Date	September 6, 2000	
	First Named Inventor	Barry N. Kreiswirth et al.	
	Group Art Unit	1643	
	Examiner Name	TBA	
Total Number of Pages in This Submission	77	Attorney Docket Number	19124.0002


RECEIVED

MAY 15 2001

TECH CENTER 1600/2900

ENCLOSURES (check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment / Response <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Statement Claiming Small Entity Status <input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition Routing Slip (PTO/SB/69) and Accompanying Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s)	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): PTO-1449 Form w/9 references
Remarks		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual name	Edward J. Naidich, Reg. No. 43,826 Swidler Berlin Shereff Friedman, LLP
Signature	
Date	May 11, 2001

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on this date: <input type="text"/>			
Typed or printed name	<input type="text"/>		
Signature	<input type="text"/>	Date	<input type="text"/>

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Atty: 19124.0002

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

#9

In re Application of:

Barry N. Kreiswirth et al.

Application No. 09/656,084

Filed: September 6, 2000

RECEIVED

MAY 15 2001

Art Unit: 1643

TECH CENTER 1600/2900

Examiner: TBA

For: **SYSTEM AND METHOD FOR TRACKING AND CONTROLLING INFECTIONS**



INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:


For insuring compliance with the applicant's duty of disclosure under 37 CFR § 1.56, the undersigned hereby submits the documents listed on the attached Form PTO-1449 for consideration by the Examiner in charge of the above-identified patent application.

These documents are being submitted before receiving a first Office Action on the merits of the above-identified patent application; or before receiving a first Office Action after filing of a Request for Continued Examination (no fee is due).

Atty: 19124.0002

The Commissioner is hereby authorized to charge payment of any deficiency in the above fee(s) or to charge any additional fees required under 37 CFR § 1.16 or 1.17 or credit any overpayment to Deposit Account No. 19-5127, Order No. 19124.0002. A duplicate copy of this authorization is attached for the Finance Branch.

Respectfully submitted,



Edward J. Naidich, Reg. No. 43,826
Swidler Berlin Shereff Friedman, LLP
3000 K Street, N.W., Suite 300
Washington, D.C. 20007-5116

Date: May 11, 2001

FORM PTO-1449

Attorney Docket: Application No.:
 19124.0002 09/656,084
 Applicant: Examiner:
 Kreiswirth et al. TBA
 Filing Date: Group Art Unit:
 September 6, 2000 1643

INFORMATION DISCLOSURE CITATION**U.S. PATENT DOCUMENTS**

Examiner Initial	Ref. No	Document Number	Date	Name	Class	Sub-Class	Filing Date
		5,660,981	8/26/1997	Grosz et al.	435	6	6/6/1994
		5,691,136	11/25/1997	Lupski et al.	435	6	8/24/1993

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Sub-Class	Translation Yes/No

OTHER DOCUMENTS (Including Author, Title, Date, etc.)

	European J. Clin. Microbiol. Infect. Dis., A. van Belkum et al. "Are Variable Repeats in the <i>spa</i> Gene Suitable Targets for Epidemiological Studies of — Methicillin-Resistant <i>Staphylococcus aureus</i> Strains?", Letters, 1996, Vol. 15, pp. 768-770.
	European J. Clin. Microbiol. Infect. Dis., H.M.E. Frenay et al. "Molecular Typing of Methicillin-Resistant <i>Staphylococcus aureus</i> on the Basis of Protein A Gene Polymorphism", Article, 1996, Vol. 15, No. 1, pp. 60-64. ✓
	European Respiratory J, M. Goyal et al., "Rapid detection of multidrug-resistant tuberculosis", 1997, Vol. 10, pp. 1120-1124.
	Proc. Natl. Acad. Sci., Martin C.J. Maiden et al., "Multilocus sequence typing: A portable approach to the identification of clones within populations of pathogenic microorganisms", March 1998, Vol. 95, pp. 3140-3145.
	Emerging Infectious Diseases, Robert J. Rubin et al., "The Economic Impact of <i>Staphylococcus aureus</i> Infection in New York City Hospitals", Jan-Feb 1999, Vol. 5, No. 1, pp. 9-17.
	Journal of Clinical Microbiology, B. Shopsin et al., "Evaluation of Protein A Gene Polymorphic Region DNA Sequencing for Typing of <i>Staphylococcus aureus</i> Strains", Nov. 1999, Vol. 37, No. 11, pp. 3556-3563.
	Website: http://cpsweb.cps.ca/english/statements/ID/id99-03.htm , Infectious Diseases and Immunization committee, Canadian Paediatric Society (CPS), "Control of methicillin resistant <i>Staphylococcus aureus</i> in Canadian paediatric institutions is still a worthwhile goal", June 12, 2000, pp. 1-8.

Examiner

Date Considered

Examiner: Initial if reference consider, whether or not citation is in conformance with MPEP §609.
 Draw line through citation if not in conformance and not considered.
 Include copy of this form with next communication to Application

RECEIVED

MAY 15 2001

TECH CENTER 1600/2900